In the aggressive subtype of triple-negative breast cancer, RAGE serves as a cell plasticity driver.

Published Date: 09 Aug 2023

Josep Villanueva, an Investigator at the Vall d'Hebron Institute of Oncology (VHIO), is the lead author of a study that was published online ahead of print in the journal Oncogene. The study demonstrates that the receptor for advanced glycation end-product (RAGE) is involved in cancer development.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Biomarker-Selected Treatment Shows Promise for Bladder Preservation in MIBC

2.

FDA Investigating Blood Cancer Risk With Gene Therapy Skysona

3.

Surviving cancer, still suffering: Survey reveals gaps in follow‑up care

4.

Charles III, King of Kings, is Cancerous.

5.

The Truth About Apple AirPods


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot